Fitzgerald Meghan 4

What Happened Meghan Fitzgerald, a director of Roivant Sciences (ROIV), exercised 70,000 stock options on March 26, 2026 by paying about $8.80 per share (total cost ~$616,000) and then sold those 70,000 shares in the open market the same day for a weighted average price of $27.45 per share (gross proceeds ~$1,921,500). The transaction shows both the option exercise (transaction code M) and the simultaneous sale (transaction code S), resulting in estimated net proceeds of roughly $1.31M before taxes and fees. A related $0.00 derivative disposition reflects surrender/conversion of the option instrument on exercise.

Key Details

• Transaction date: 2026-03-26; Form 4 filed: 2026-03-30 (filing appears timely).
• Exercise: 70,000 shares at $8.80 per share — total paid ≈ $616,000.
• Sale: 70,000 shares at weighted average $27.45 per share — gross proceeds ≈ $1,921,500.
• Sale price range (per footnote): $27.32 to $27.80; reporting person can provide exact breakdown on request.
• Footnote F2: the exercised options were fully vested awards.
• Shares owned after the transaction: not reported in the provided extract.

Context This is a same-day exercise-and-sell (cashless-style) transaction: the director converted vested options into common shares and sold them immediately. Such transactions are common for covering exercise costs, tax withholding, or realizing gains and do not necessarily indicate a change in the insider’s view of the company. The filing is factual and does not state any 10b5-1 plan or tax-withholding specifics.